Greenwich LifeSciences Screens Over 1,000 Patients in FLAMINGO-01 Breast Cancer Trial.

Greenwich LifeSciences has screened over 1,000 patients for its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100 to prevent breast cancer recurrences. The trial is being conducted at 40 US sites and 100 EU sites, with a screening rate of approximately 150 patients per quarter. The company is considering continuing enrollment in both HLA-A*02 and non-HLA-A*02 arms until interim analyses are conducted.